{"public_id":"co_a7a3894478d4f5347be438d8c3d9bef2","status":"active","merged_into_public_id":null,"resolved_public_id":"co_a7a3894478d4f5347be438d8c3d9bef2","name":"FDG-PET scan","description":"An interim fluorodeoxyglucose positron emission tomography examination used to assess disease activity after initial chemotherapy.","aliases":["2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography","FDG-PET","PET-2"],"types":["measurement technique","prognostic test"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":25100921,"title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.","citation_count":802,"url":"https://sah.borca.ai/papers/25100921"}],"claims":[{"public_id":"cl_09b174ae2e75f65575a130e8d33b3a10","text":"PET-2 emerges as the single most important tool for planning risk-adapted treatment in advanced Hodgkin's lymphoma.","corpus_id":25100921,"url":"https://sah.borca.ai/claims/cl_09b174ae2e75f65575a130e8d33b3a10"},{"public_id":"cl_a36e5890188d474ef7b490f46f0d5ad8","text":"Positive early interim FDG-PET after two courses of ABVD is strongly associated with much poorer 2-year progression-free survival than negative PET-2 in advanced Hodgkin's lymphoma.","corpus_id":25100921,"url":"https://sah.borca.ai/claims/cl_a36e5890188d474ef7b490f46f0d5ad8"},{"public_id":"cl_ee936a6a39511657b0a0a51544468e9b","text":"PET-2 is the only significant prognostic factor in multivariate analysis, outperforming the International Prognostic Score and other clinical variables.","corpus_id":25100921,"url":"https://sah.borca.ai/claims/cl_ee936a6a39511657b0a0a51544468e9b"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_a7a3894478d4f5347be438d8c3d9bef2","url":"https://sah.borca.ai/concepts/co_a7a3894478d4f5347be438d8c3d9bef2"}